At present there are no drugs for the treatment of chronic liver fibrosis that have been approved by the Food and Drug Administration of the United States. Telmisartan, a small-molecule antihypertensive drug, displays antifibrotic activity, but its clinical use is limited because it causes systemic hypotension. Here, we report the scalable and convergent synthesis of macromolecular telmisartan prodrugs optimized for preferential release in diseased liver tissue. We have optimized the release of active telmisartan in fibrotic liver to be depot-like (that is, a constant therapeutic concentration) through the molecular design of telmisartan brush-arm star polymers, and show that these lead to improved efficacy and to the avoidance of dose-limiting hypotension in both metabolically and chemically induced mouse models of hepatic fibrosis, as determined by histopathology, enzyme levels in the liver, intact-tissue protein markers, hepatocyte necrosis protection and gene-expression analyses. In rats and dogs, the prodrugs are retained long term in liver tissue, and have a well-tolerated safety profile. Our findings support the further development of telmisartan prodrugs that enable infrequent dosing in the treatment of liver fibrosis.
L iver cirrhosis, the final stage of hepatic fibrotic disease, is a rising global health issue that claimed over 1 million lives (2% of global deaths) in 2010 1, 2 . Within 5 years of being diagnosed with decompensated cirrhosis, the overall patient survival rate is 45% 3 . This disease, for which there are currently no Food and Drug Administration (FDA)-approved therapies, can result from several insults, including non-alcoholic steatohepatitis (NASH), alcoholic liver damage, viral hepatitis and toxic damage 4 . The pathogenesis involves deregulated extracellular matrix production, including activated hepatic stellate cells (HSCs) and stromal fibroblasts. In preclinical studies, inhibition of components of the renin-angiotensin system (RAS) with small-molecule angiotensin II antagonists has been shown to limit stromal cell activation and proliferation, inflammation and oxidative stress associated with liver fibrosis [5] [6] [7] . For example, telmisartan (TEL), a known angiotensin II type 1 receptor blocker (ARB) and a widely used antihypertensive drug, has been reported to ameliorate hepatic fibrosis 8 . Despite this potential application, the clinical translation of ARBs, including TEL, for non-cardiovascular applications has been hindered by dose-limiting hypotension 9, 10 . Such limits are even more problematic in advanced liver fibrosis where systemic hypotension often develops and is further accentuated by systemic drug accumulation due to decreased liver metabolism 11 .
To tackle these challenges, we set out to design a macromolecular TEL prodrug with an optimized biodistribution (BD) to fibrotic tissue and a tunable pharmacokinetic (PK) profile to ensure preferential release of active TEL in the diseased microenvironment. We envisioned that a macromolecular-conjugate-mediated ARB delivery strategy may overcome the poor therapeutic index often associated with therapies for chronic fibrotic disorders, and provide a clinically translatable therapeutic technology for liver fibrosis 12 .
Macromolecular drug carriers can alter the biodistribution of smallmolecule drugs, with the liver being a major reservoir and clearance organ for neutrally charged ~10-50 nm objects 13, 14 . Moreover, macromolecules in this size range are able to pass the leaky vasculature associated with chronic inflammatory disease and accumulate in the fibrotic microenvironment [15] [16] [17] . Despite these advantages, there is often an inverse relationship between scalability and the potential for modularity and complexity of macromolecular prodrugs that limits the rational and modular optimization of material properties in vivo and ultimately hinders their clinical translation ( Fig. 1a ). Materials that physically encapsulate their therapeutic payload have achieved clinical success in specific disease contexts; however, their formulation depends on the chemical properties of the drug, which limits the ability to vary properties such as drug identity, hydrodynamic diameter (D h ) and drug release kinetics (Fig. 1a, top left) 18 . In contrast, the reproducible scaling of advanced material architectures that rely on linear multi-step synthetic routes is difficult and may preclude rapid property optimization (Fig. 1a , bottom right) 17 . Several recent discussions have highlighted the fact that most nanomedicines reported in the literature do not translate to clinical applications 19, 20 . Although this may be expected for experimental drugs, in our view, this dearth of examples is in part due to a lack of modular synthesis strategies for macromolecular prodrugs that are both versatile and scalable. Here, we present such a strategy for the rational design and optimization of a TEL-based convergent prodrug that reverses liver fibrosis in vivo. Our synthesis is demonstrated to be highly reproducible up to the 100 g scale, which establishes a benchmark for the scalable synthesis of complex macromolecular prodrugs required for drug development and in vivo safety pharmacology studies.
BASPs have chemically tunable release kinetics in vitro.
Our approach involves a unique macromolecular architecture-the brush-arm star polymer (BASP)-the synthesis of which was intended to be modular and scalable [21] [22] [23] [24] [25] [26] . BASPs are prepared in a convergent ring-opening metathesis polymerization (ROMP) process whereby norbornene-based drug-conjugated macromonomers (MMs) are polymerized to generate living bottlebrush polymer 'arms' that are subsequently crosslinked 23 . The composition and size of BASPs depends on the macromonomer and crosslinker structures and the ratio of polymerization initiator to macromonomer and crosslinker, respectively, all of which can be optimized in parallel for specific applications. Moreover, this approach enables rational control of drug release kinetics through linker design. For example, TEL contains a carboxylic acid functional group that we reasoned could serve as a linker site for conjugation via esterification ( Fig. 1b ). To identify the ester structure with optimal TEL release kinetics and therapeutic index in vivo, we began our study with the synthesis of three azide-functionalized (N 3 ) TEL-esters-TEL-1-N 3 , TEL-x-MM x = 1, 2 or 3 3:
Increasing TEL release rate m equiv. TEL-2-N 3 and TEL-3-N 3 -from alcohols 1, 2 and 3, respectively ( Fig. 1b) . These compounds were devised to provide increasing rates of esterase-mediated hydrolysis (that is, TEL release) via successive stabilization of the alkoxide hydrolysis products through both resonance and inductive effects . To test the validity of this design,  TEL-1-N 3 , TEL-2-N 3 and TEL-3-N 3 were conjugated to alkynecontaining norbornene-polyethylene glycol (PEG) macromonomer 4 via copper-catalysed azide alkyne cycloaddition (CuAAC) to yield water-soluble macromonomers TEL-1-MM, TEL-2-MM and TEL-3-MM (Fig. 1b) . The pseudo-first-order rate constants (± s.d.) for release of TEL from these macromonomers (in porcine liver esterase (100 units ml −1 ) at 37 °C in phosphate-buffered saline (PBS) solution at pH 7.6) were 2.9 ± 0.1 × 10 −3 min −1 (TEL-1-MM), 4.6 ± 0.4 × 10 −3 min −1 (TEL-2-MM) and 8.8 ± 0.7 × 10 −3 min −1 (TEL-3-MM) ( Supplementary Fig. 1 ). Thus, the electron-deficient difluorophenyl-based linker (TEL-3-MM) provides a threefold greater release rate than the tetraethylene glycol linker (TEL-1-MM) under these conditions. Moreover, while all of these MMs showed nearly complete TEL release after ~1 day in the presence of esterase in vitro, they showed minimal release (< 15%) after nearly a week in PBS buffer at 37 °C in the absence of esterase. Given that esterases are typically present at lower levels in plasma and at higher concentrations in intracellular lysosomal compartments of inflamed tissue 27 , our strategy could favourably preclude the dose-limiting bloodpressure-lowering systemic effects of TEL by a preferential esterasemediated release of TEL in the fibrotic liver microenvironment. Next, we turned our attention to the synthesis of TEL-x-BASPs (where x corresponds to linker 1, 2 or 3) via ROMP of these TELester macromonomers followed by crosslinking with a degradable acetal-based crosslinker (AXL) ( Fig. 1c ). With the ultimate goal of clinical translation of these materials, we developed an operationally simple and scalable semi-batch BASP synthesis protocol. In a typical reaction, Grubbs third-generation catalyst (G3, Fig. 1c ) was added to a 0.05-0.1 M solution of TEL-x-MM (20 mg to 2 g) in 1,4-dioxane (G3:TEL-x-MM = 1:N) to generate a living TEL-bottlebrush polymer with an average degree of polymerization of N. Next, a 0.1 M solution of AXL (m equiv.) in 1,4-dioxane was added by syringe pump at a rate of 1 equiv. min −1 (Fig. 1b ). After completion of the crosslinking process as determined by gel permeation chromatography (GPC) ( Supplementary Fig. 2 ), ethyl vinyl ether (EVE, ~100 equiv.) was added to quench the reaction. We screened m and N values to identify suitable ratios for the synthesis of TEL-BASPs with narrow size distributions and D h of ~25-30 nm, as this size range is considered optimal for passage through the leaky vasculature of fibrotic diseased tissues 16, 28, 29 . We were particularly interested in understanding the impact of m and N on BASP homogeneity, both in terms of size and size distribution, as well as bottlebrushto-BASP percent conversion p. Using TEL-2-MM as a test macromonomer, TEL-2-BASPs were prepared using m = 7, 10 and 13; for each m value a variety of N values were evaluated (Table 1) . GPC was used to assess p ( Supplementary Fig. 3 ), while dynamic light scattering (DLS) was used to measure D h as functions of m and N. For the range of m and N studied, p varied from 82% to 97% (Table 1 ). Larger p values were obtained with higher N and lower m. D h was fairly consistent, ranging from ~20 to 30 nm; however, for a given m, D h increased with N ( Supplementary Figs. 8-16 ). Although it is possible to achieve p values as high as 97% in this system, this increased conversion comes at the expense of the TEL mass fraction, which generally decreases with increased N ( Table 1) . We conducted control experiments to confirm that the semi-batch protocol described herein is superior (as assessed by p value and dispersity) to our previous methods for BASP synthesis ( Supplementary Fig. 4 ). Based on these results, we proceeded with the m = 10, N = 9 stoichiometry, as it provided an optimal combination of p (84% wt/wt) and TEL loading (11% wt/wt theoretical; 10.4 ± 1.1% wt/wt experimental, see Supplementary Section H for details).
TEL-2-BASP displays optimal liver BD and PK. To select the optimal TEL linker for scale-up, the BD and PK profiles of TEL-2-BASP and TEL-3-BASP were investigated; TEL-1-BASP was not pursued further based on the sluggish TEL release kinetics observed for TEL-1-MM. Fluorophore-conjugated TEL-2-BASP and TEL-3-BASP were prepared from TEL-2-MM and TEL-3-MM, respectively (m = 10), a cyanine7.5-fluorophore-labelled (Cy7.5) macromonomer (0.01 equiv., see Supplementary Section B for synthetic details) and AXL (N = 9 equiv.) following our optimized semi-batch protocol described in the previous section. After dialysis, sterile filtration and lyophilization, TEL-2-BASP and TEL-3-BASP were examined in vivo. The lyophilized BASP product was reconstituted in PBS (40 mg ml −1 ), sterile-filtered and administered intravenously (i.v., 200 mg kg −1 ) to BALB/c mice (n = 15) with blood and liver tissue samples collected for longitudinal liquid chromatography with tandem mass spectrometry (LC-MS/MS) measurements of both released and polymer-conjugated TEL (see Supplementary Section I.2 for additional details). As shown in Fig. 2a , over the first 10 days following administration, TEL-3-BASP released significantly more TEL in blood compared to TEL-2-BASP. Given our goal of reducing the concentration of free TEL in blood, we selected TEL-2-BASP for analysis of liver PK (Fig. 2b) . The results from this study consistently showed ~100-fold greater concentration of released TEL in the liver compared to blood samples. In addition, the concentration of polymer-conjugated TEL was > 100-fold greater than released TEL in the liver, even 10 days post i.v. administration. The concentration of released TEL reached a steady state over this time period. These data suggest that TEL-2-BASP acts as TEL-releasing depot in the liver, which we hypothesized would enable infrequent dosing compared to generic TEL. Lastly, ex vivo, near-infrared fluorescence images (Cy7.5-fluorophore: λ ex = 700 nm, λ em = 800 nm) of organs collected from a representative animal killed 7 days post TEL-2-BASP administration revealed preferential accumulation of fluorescence in the liver and the spleen (Fig. 2c ).
TEL-2-BASP synthesis is scalable.
Having identified TEL-2-BASP as our optimal candidate for further translation, we turned our attention to scaling up the synthesis of this macromolecular prodrug. We first investigated the performance of our optimized protocol in the context of a 2.0 g scale TEL-2-BASP synthesis. DLS and transmission electron microscopy (TEM) analysis of TEL-2-BASP prepared on the 0.02 g scale ( Fig. 3a ) versus the 2 g scale ( Fig. 3b ) revealed very similar particle sizes and size distributions; p was also similar for these batches. Next, the same procedure was repeated on a 100 g scale (a 5,000-fold increase over the 0.02 g scale reaction).
Here again, the TEL-2-BASP produced from this batch had the same size and size distribution as the smaller-scale batches (Fig. 3c) ; however, in this reaction p was improved to 93%. We believe that the improved conversion in the larger-scale process is due to superior mixing achieved by the use of a shaft-driven mechanical stirrer rather than a magnetic stir bar. Altogether, these results clearly demonstrate the scalability of our brush-first ROMP TEL-2-BASP synthesis protocol.
TEL-2-BASP is well tolerated in mice.
To determine the safety and efficacy of TEL-2-BASP, we conducted single and repeat-dose safety and toxicology studies in mice. First, to benchmark the potential blood-pressure-lowering effects of TEL-2-BASP versus generic TEL (administered at the equivalent dose to the human therapeutic blood-pressure-controlling dosage of 10 mg kg −1 perorally), three groups of mice (n = 8 per group) were dosed with either vehicle control, generic TEL, or TEL-2-BASP at three times the human therapeutic dosage equivalent to generic TEL (300 mg kg −1 BASP based on 10% TEL loading). As expected, administration of generic TEL led to a statistically significant, transient drop in both systolic ( Fig. 4a ) and diastolic ( Fig. 4b ) blood pressures (two-tailed Student's t-test, P < 0.0001) 2 h after administration and returned to normal physiological levels within 24 h, consistent with a reported t 1/2 of 6 h and once-daily dosing. In normotensive patients, such systemic blood pressure lowering limits the more widespread usage of generic ARBs to treat fibrotic disorders. In addition, blood pressure lowering is prohibitive for use in patients with advanced liver fibrosis/cirrhosis that have developed systemic hypotension. In contrast to generic TEL, even at three times the concentration of generic TEL, TEL-2-BASP did not produce a drop in systolic or diastolic blood pressures after 2 h (first dose) or following a repeat dosing (second dose) given to the same animals 7 days after the first dose. These results agree with the blood PK data for TEL-2-BASP ( Fig. 2) , and support our hypothesis that a macromolecular TEL prodrug with appropriate linker structure can prevent the undesired blood-pressure-lowering effects of generic TEL concomitant with achieving significant TEL exposure in fibrotic liver tissue.
To further assess the safety of TEL-2-BASP, mice were given one or multiple doses of the Cy7.5-fluorescently labelled compound. After a single dose, 25 different tissues were collected from each mouse at day 1, day 3 or weeks 1, 3, 5, 7, 9 or 12 post dosing. Mice receiving three repeat doses weekly had their tissues collected at weeks 3, 7 or 12 post dosing. The emission of the Cy7.5 label in the various tissues was assessed by whole organ fluorescence; liver, spleen and kidney were the tissues with the highest levels of fluorescence. From mice receiving a single dose of TEL-2-BASP, liver tissues were homogenized (n = 3 animals per time point), resolved on an SDS-PAGE gel and imaged ( Supplementary Fig. 17 ). For each time point, the relative Cy7.5 signal was quantified, and the results revealed a seven-to eightfold decrease in overall Cy7.5 signal over a 12-week period (Fig. 4d ). Anti-PEG enzyme-linked immunosorbent assay (ELISA) on the same liver homogenate samples also showed a trend of PEG clearance during the course of the study ( Fig. 4e and Supplementary Fig. 18 ). Combined, these results provide support for eventual clearance of TEL-2-BASP (and smaller polymeric degradation products derived from TEL-2-BASP), despite the seemingly long t 1/2 . Moreover, haematoxylin and eosin (H&E)-stained sections of the formalin-fixed tissues were submitted for blinded analysis by an American College of Veterinary Pathology Board-Certified Veterinary Pathologist, which included assessment of the presence or absence of cellular cytoplasmic vacuoles that have been previously associated with PEGylated test articles in other settings. No PEG-induced vacuoles were observed in any tissues examined ( Fig. 4c) 30, 31 .
TEL-2-BASP is well tolerated in higher species.
Having established that TEL-2-BASP is well tolerated in mice, we next conducted dose escalation and safety toxicology studies in Sprague-Dawley rats, a species commonly used for drug safety/toxicity assessment as part of Investigational New Drug (IND)-enabling studies. Following M3(R2) regulatory guidance 32 , rats were first dosed up to the maximum feasible dose (MFD), which is 5 ml kg −1 for a slow-push bolus i.v. injection. This dose corresponds to 500 mg kg −1 of TEL-2-BASP, which, based on solubility and viscosity considerations, was prepared at 100 mg ml −1 . Importantly, no test article-related clinical observations or effects on body weight, food consumption, haematology or organ weights in any of the tested dose groups (50, 150 and 500 mg kg −1 i.v.) were found after a single dose. At necropsy (day 7 post dosing), there were no test article-related macroscopic or microscopic findings in the tissues examined (liver, kidney, spleen, brain, choroid plexus, lung and heart), and there were no statistically significant differences in serum chemistry parameters between the control group and the test article-treated groups ( Supplementary Tables 1 and 2) . Similarly, the differential blood cell counts were normal, showing no evidence of immune activation or blood coagulation, as has been reported for some PEG-based materials. Importantly, blood PK analysis over the course of 7 days showed dose proportionality for both the conjugated and released drug ( Fig. 4f ) (n = 12; 6 male and 6 female) and showed no sex differences in the drug release profiles. Finally, the toxicity and tolerability of TEL-2-BASP was studied in beagle dogs, a species widely recognized to be appropriate for repeat-dose toxicity studies. Briefly, TEL-2-BASP was first administered to a single beagle (slow-push bolus i.v. injection, 5 ml kg −1 ) of each sex (n = 1 animal per sex) at escalating doses of 36, 100 and 500 mg kg −1 . Injections were spaced approximately 1 week apart. In addition, repeat injections were made at the MFD (500 mg kg −1 ) such that a group of male dogs and a group of female dogs (n = 2 animals per sex) received two 500 mg kg −1 injections of TEL-2-BASP 1 week apart. All dogs were telemetrized to enable monitoring of EKG, including blood pressure, pulse pressure and pulse. The clinical observations and post-necropsy investigations were similar to those determined for rats, confirming the safety of TEL-2-BASP in higher species. Remarkably, there were neither significant differences in serum chemistry values ( Supplementary  Tables 3 and 4 ) nor observed blood pressure changes even at the repeat MFDs; these data are consistent with plasma PK measurements of released TEL well under 400 ng ml −1 (Supplementary Figs.  19-22 ). Altogether, we conclude that TEL-2-BASP has an excellent safety profile and is well tolerated in both rodents and dogs.
TEL-2-BASP shows sustained release and reduces fibrosis.
The in vivo activity of TEL-2-BASP was first assessed in the stelic animal model (STAM) metabolic mouse model of NASH, where the liver disease is driven by a combination of diabetes and a high-calorie diet 33, 34 . Specifically, NASH was induced in male mice (C57BL/6) by injection of a streptozotocin (STZ, 200 µ g) solution 2 days after birth, followed by feeding a high fat diet (HFD) starting at 4 weeks of age. The animals (n = 7 per group) were maintained on HFD for 9 weeks and administered two doses of TEL-2-BASP (300 mg kg −1 i.v.) at the beginning of weeks 6 and 7 of the HFD. Animals were then killed and assessed for liver fibrosis by PicroSirius Red (PSR) staining ( Supplementary Fig. 23a ). Although the TEL-2-BASP treatment showed a statistically significant (P < 0.05) reduction of fibrosis compared to that of the untreated animals ( Supplementary  Fig. 23b ), the STAM model displayed only a mild fibrosis phenotype, consistent with this being a diet-induced model of non-alcoholic fatty liver disease. Hence, we next turned our attention to the effects of TEL-2-BASP in a chemically induced carbon tetrachloride (CCl 4 ) mouse model, which is characterized by a pronounced fibrosis phenotype as evident from our biomarker analyses (vide infra, Fig. 5 ). Specifically, three groups of mice (n = 10 to 12 per group) were challenged with 1 ml kg −1 of CCl 4 (i.p. twice weekly for 6 weeks) to induce liver fibrosis. Fibrosis was confirmed by week 4 ( Fig. 6 and Supplementary Figs. 24-31 ) based on histology (H&E and PSR), immunohistochemistry and digital immunofluorescent quantitative analyses (α -smooth muscle actin, nestin and collagen-1). During the last 2 weeks of continuous CCl 4 administration, diseased animals were treated with equivalent amounts of TEL over a 2-week period: either 14 doses of generic TEL (10 mg kg −1 daily perorally, Fig. 5a , grey arrows) or two total doses of TEL-2-BASP (700 mg kg −1 i.v; 10% TEL loading wt/wt, Fig. 5a , orange arrows) leveraging the sustained release of TEL from TEL-2-BASP observed in Fig. 2b . It should be noted that a 700 mg kg −1 TEL-2-BASP dosage is feasible for human translation based on allometric scaling 35 . With our dosing regimen, all animals received, on average, the same amount of TEL over the 2-week period (140 mg kg −1 ). In the CCl 4 liver fibrosis model, TEL-2-BASP showed efficacy even during ongoing CCl 4 intoxication based on blood biochemistry ( Supplementary Fig. 32 ), liver function, histology and biomarker endpoints ( Fig. 6 and Supplementary Figs. 24-31 ). Moreover, both generic TEL and TEL-2-BASP-treated groups showed no significant body weight change compared to healthy or untreated diseased animals over the course of the 14-day treatment regimen (Fig. 5a ). Terminal liver tissue PK analysis of released and bound TEL revealed that more than 10% of the systemically injected dose of TEL-2-BASP was present in the diseased liver 7 days post last dosing (Fig. 5b) . Moreover, the concentration of polymer-conjugated TEL (221,689 ng g −1 ) was ~170-fold higher than the concentration of generic TEL (6,720 ± 619 ng g −1 ) and the amount of released drug from TEL-2-BASP (1,843 ± 118 ng g −1 ) was within threefold of generic TEL; the large concentration of TEL prodrug in the diseased liver acts as a depot to provide a constant therapeutic concentration of released TEL long after the generic TEL dosage is cleared.
Importantly, consistent with the superior biodistribution to diseased liver tissue, TEL-2-BASP exhibited similar to improved efficacy compared to generic TEL for all endpoints examined. At the 6-week endpoint, liver enzyme levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TB) were significantly decreased in TEL-2-BASP-treated animals compared to untreated or those treated with generic TEL ( Supplementary Fig. 32 ). Analyses of intact-tissue protein biomarkers based on immunohistochemistry and quantitative digital imaging of immunofluorescence, as well as histopathology, confirmed that TEL-2-BASP exerted a significantly superior protective effect against periportal hepatocyte necrosis ( Fig. 6 and Supplementary Figs. 24-31 ). It also was more efficacious in restoring glycogen content ( Supplementary  Fig. 33 ) compared to generic TEL. Histopathology scoring for necrosis and inflammation ( Supplementary Figs. 27-29 and 34 ) and independent apoptosis scoring through cleaved caspase-3 quantification ( Supplementary Fig. 30a ) both showed more than a fourfold reduction in the liver cell death score for TEL-2-BASPtreated animals compared to tissue from the untreated groups. Moreover, stage-specific embryonic antigen 1 (SSEA1) levels were significantly decreased for TEL-2-BASP-treated animals compared to those treated with generic TEL ( Supplementary Fig. 30b ). Along with significant hepatocyte protection by TEL-2-BASP treatment, images stained for α -smooth muscle actin, nestin and collagen-1 ( Supplementary Fig. 31 ), as well as scoring of PSR histological images by a blinded pathologist ( Fig. 6 and Supplementary Figs. 24-29) , strongly support the notion that TEL-2-BASP efficacy is due at least in part to reversal of fibrosis. In a repeat CCl 4 efficacy study, we found that TEL-2-BASP reduced mRNA expression from 13 genes representative of inflammation and extracellular matrix synthesis and turnover in fibrotic tissues, lending further credence to an antifibrotic mechanism of action via microenvironment modulation (Fig. 5c ). From these data, collectively, we conclude that despite an infrequent dosing paradigm (weekly), the efficacy of TEL-2-BASP significantly exceeds that of generic TEL administered daily in this mouse model of liver fibrosis.
Outlook. We have shown that optimization of the design and synthesis of macromolecular telmisartan prodrugs can enable superior biodistribution and release of the active drug in fibrotic diseased tissues, concomitant with a low release of the active drug systemically. The superior efficacy and unique pharmacokinetic profile of TEL-2-BASP, with a depot-like release and long half-life of active released TEL in the diseased tissue, suggests that an attractive infrequent dosing schedule might be feasible in the clinic. Overall, TEL-BASPs may enable tissue-microenvironment-targeted therapies for chronic inflammatory and fibrotic conditions. Moreover, the modularity and scalability of BASP synthesis demonstrated here make BASPs attractive for a range of additional applications in prodrug design.
Methods
Detailed methods are described in the Supplementary Information.
General procedure for synthesis of TEL-MM. A 20 ml scintillation vial was charged with one of three TEL-N 3 compounds (TEL-1-N 3 , TEL-2-N 3 or TEL-3-N 3 ) or Cy7.5-N 3 , PEG-Alkyne-MM and a stir bar. In a nitrogen-filled glovebox, the reagents were dissolved in CH 2 Cl 2 (1 ml CH 2 Cl 2 per 100 mg PEGalkyne-MM), to which was added ~3 equiv. of copper(i) acetate. The reaction was stirred until consumption of PEG-alkyne-MM (~1 h) was observed by LC-MS analysis. As the relative extinction coefficients of the TEL-N 3 and PEG-alkyne-MM are vastly different (the former being much larger), it is important that a small amount of TEL-N 3 is visible by LC-MS. It is difficult to remove unreacted PEG-Alkyne-MM and its presence is detrimental to the subsequent ROMP processes. The crude product was purified by preparative-high-performance liquid chromatography (prep-HPLC) or prep-GPC. For material purified by prep-HPLC, fractions containing product were concentrated by rotary evaporation and the resulting residue was redissolved in CH 2 Cl 2 and dried over sodium sulfate. After concentration by rotary evaporation, the solid polymer was washed with cold diethyl ether by centrifugation of solids and decanting of the ether. This wash step was repeated three times to afford the desired TEL-MM or Cy7.5-MM as white and green solids, respectively. For material purified by prep-GPC, the crude reaction mixture was first concentrated and dissolved in minimal CH 2 Cl 2 . The solution was passed through a short column of neutral alumina (~10% MeOH/CH 2 Cl 2 ) and the eluent was concentrated by rotary evaporation. Then, after purification by prep-GPC, fractions containing product were concentrated by rotary evaporation. The resulting solid was washed with cold diethyl ether three times (as above) to afford TEL-MM as a white powder.
General procedure for synthesis of TEL-BASP. TEL-2-MM (2.00 g, 9.9 equiv.) and Cy7.5-MM (20.1 mg, 0.1 equiv.) were added to a 40 ml vial charged with a Tefloncoated stir bar and septum. In a nitrogen-filled glovebox, the following solutions were prepared: G3 (49.8 mg in 2.49 ml 1,4-dioxane = 0.02 g ml −1 ) and AXL (304 mg in 5.24 ml 1,4-dioxane = 0.1 M). To a stirred solution of MM (3.07 ml 1,4-dioxane) was added an aliquot of G3 (1.75 ml, 1 equiv.) as a single stream. The final volume in the reaction vial (3.07 ml + 1.75 ml = 4.82 ml) afforded an MM concentration of 0.1 M. On initiating ROMP, the reaction was allowed to proceed for 15-20 min before removal from the glovebox and was then transferred immediately to a Schlenk line under positive N 2 pressure. A 10 ml syringe fitted with a stainless steel needle was charged with the solution of AXL (5.24 ml, 0.1 M), and the assembly was placed into a syringe pump (KD Scientific, Legato 100). The tip of the stainless steel needle was carefully placed just under the level of the reaction medium, and AXL solution (4.34 ml, 9 equiv.) was directly infused at a rate of 1 equiv. min −1 .
On completion of AXL addition, the crosslinking reaction was allowed to proceed for ~120 min before quenching with ethyl vinyl ether (0.300 ml). The material was diluted with nanopure H 2 O (~9.5 ml, 1:1 dilution) before being transferred to dialysis tubing (RC, 8 kDa molecular weight cutoff) for dialysis against nanopure H 2 O (15 l, 3 × 2-3 h cycles). The contents of the dialysis tubing were then transferred to clean 20 ml vials and lyophilized (at least 24 h) to afford a dry powder (2.1 g, 90%).
In vitro TEL release assay. Approximately 5 mg of a given MM (TEL-1-MM, TEL-2-MM or TEL-3-MM) was weighed into a clean 4 ml vial. Separately, a stock solution of porcine liver esterase (17 units per mg solid) was made from 24 mg of solid esterase powder and 4 ml of PBS (pH 7.6) such that the final activity of esterase in solution was ~100 units per ml. Each vial containing 5 mg of a given MM was dissolved in 1 ml of the esterase stock solution. The polymer solutions were briefly vortexed and immediately portioned into 1 ml vials with Teflon-coated caps. All vials were sealed and placed in a 37 °C static incubation oven. At each time point, a vial for a given MM was removed from the incubation oven and cooled to room temperature. To each vial was added 200 µ l dimethylsulfoxide, and the resulting solution was briefly vortexed before filtering through a 0.45 µ m nylon syringe filter. Analysis by LC provided insight into the amount of TEL-MM remaining at a given time point.
BD and PK analysis in vivo. The lyophilized BASP product was reconstituted in PBS (40 mg ml −1 ), sterile-filtered, and administered i.v. (200 mg kg −1 ) to BALB/c mice (n = 15) with blood and liver tissue samples collected for longitudinal LC-MS/MS measurements of both free (unconjugated) and polymer-conjugated TEL. The presence of polymer was quantified in liver homogenate by Cy7.5 imaging after resolution on an SDS-PAGE gel following a higher dose of TEL-2-BASP (300 mg kg −1 ). Similarly, PEG clearance was measured by anti-PEG ELISA ( Fig. 4e and Supplementary Fig. 17 ). For the ELISA assay, liver tissues were homogenized and lysates prepared in T-PER reagent (tissue protein extraction reagent, ThermoFisher Scientific) and normalized for protein concentration. Anti-PEG ELISA was performed on the liver homogenates following standard procedures (PEGylated protein ELISA kit, ab133065, Abcam). Briefly, test samples were added to a 96-well plate coated with monoclonal antibody specific to PEGylated protein. This procedure was followed by addition of biotinylated PEG protein and incubation at room temperature for 30 min. The wells were washed to remove excess unbound protein and a solution of streptavidin-HRP conjugate was added. Following incubation, excess reagents were washed and TMB substrate was added and further incubated at room temperature. Stop solution was then added and optical density (OD) absorbance was measured at 450 nm using a SpectraMax plate reader. Animals were assigned to treatment groups (n = 10-12 animals per group) by randomization in BioBook software to achieve a similar group mean weight, which provided for control of bias. Additionally, disease animals (CCl 4 group) were assigned to the different groups according to their ALT/AST levels first and body weight second after 4 weeks of CCl 4 treatment. Animals were injected intraperitoneally with CCl 4 (i.p.) 1 ml kg −1 (4 ml kg −1 of 25% CCl 4 in olive oil), twice per week for a total period of 6 weeks with test agents administrated during the last 2 weeks of study. Induction of fibrosis was assessed first in both male and female BALB/c mice by PSR staining of harvested liver tissue. The aggressive, bi-weekly, intraperitoneal CCl 4 dosing regimen led to a more consistent level of fibrosis in female mice compared to male mice. The male mice displayed higher variability and mortality rates during the 6-week continued CCl 4 induction. Hence, female mice were chosen so there would be consistency across treatment groups when comparing effect sizes. TEL was formulated from dry powder in 0.5% hydroxyl propyl methyl cellulose (HPMC) with 0.2% Tween-80 solution, and the test agent was administrated by daily oral gavage. TEL-2-BASP (lyophilized material) was reconstituted in PBS on the day of dosing (70 mg ml −1 solution), sterile-filtered (0.22 μ M) and dosed intravenously according to body weight (that is, 200 μ l per 20 g animal; total of two doses). At the conclusion of the study, the whole liver tissue was flushed quickly with ice-cold PBS, blotted briefly on a paper towel, and weighed. Liver tissue was dissected into pieces: the right lobe was fixed in 10% neutral formalin; the left lobe was shock frozen in liquid nitrogen for tissue PK analysis. For tissue fixation, tissues were placed into 10% neutral buffered formalin (NBF; 20× volume) and incubated overnight (at least 12 h) at 4 °C. The following day, the tissue was moved to room temperature for 4-5 h, before being washed twice with PBS and stored at 4 °C for subsequent paraffin embedding and immunohistochemical processing. Animal blood samples (non-fasting) were collected at sacrifice for terminal PK analysis (whole blood in EDTA tubes) and plasma was processed by refrigerated centrifugation within 30 min of collection (2,000 g for 10 min at 4 °C). Plasma levels of ALT, AST and TB were measured using an automatic biochemistry analyser (HITACHI 7020).
Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. All data supporting the findings of this study are available within the paper and its Supplementary Information. For the initial studies, we used n = 15 for mouse safety (BD/PK), n = 3 animals for 5 different time points (minimum number of animals used to obtain statistically significant PK and BD data). For rat safety and PK, n = 12 (6 animals per group per sex) were used for increased statistical significance when assessing safety of TEL-2-BASP in rodents. For dog safety, n = 2 (1 animal per sex) for dose-escalation studies and n = 4 (2 animals per sex) for repeat dosing. The minimum number of Beagle dogs were used while still obtaining statistically relevant data on the effects of repeat dosings at high TEL-2-BASP levels.
For efficacy studies in mice, n = 7 male mice per group were used for the STAM NASH model and n = 10 -12 animals per group were used for the CCl4 model to ensure that statistically significant results were obtained in the context of advanced disease progression.
Data exclusions
Describe any data exclusions.
Pathological scoring and the corresponding stained images (H&E and PSR) were analyzed for 6 (of the 10 -12 total) random animals per group in the CCl4 study.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All data (blood/organ PK values, BD, body weights, blood pressure, gene expression, serum biochemistry and histology) are reported from a statistically significant group of animals (n = 3+) and are representative of results from different animals. Furthermore, PK profiles were consistent among a statistically significant number of grouped rodents (i.e. separate studies using healthy BALB/c mice and Sprague Dawley rats). Liver-fibrosis efficacy data, as judged by blood biochemistry and histological stained images, was consistent among two wellestablished models used to assess liver fibrosis (i.e. carbon tetrachloride and high-fat diet STAM models).
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Animals were allocated into study groups on the basis of body-weight randomization. For the carbon tetrachloride efficacy study, diseased animals were randomized into groups first on the basis of ALT/AST levels, followed by secondary randomization by body weight.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not possible during dosing, as different concentrations of TEL-2-BASP needed to be used for various groups. However, blinding was used during the preparation of all histological scoring reports by Dr. Roderick Bronson (Board Certified Veterinary Pathologist).
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
GraphPad Prism 7 software was used for the statistical analyses presented. NMR data was processed with MestReNova NMR software.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
Complete synthetic details for the brush-arm star polymers used in this study (along with relevant chromatographic, spectroscopic, and spectrometric characterization data), and photographs of the reaction setup on various scales, are provided.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
A monoclonal antibody specific to PEGylated protein was used for anti-PEG ELISA. 96-well plates pre-coated with this antibody were used as received from the vendor (Abcam, ab133065). In addition, standard antibodies were used directly from the vendors for the immunohistochemistry assays: cleaved caspase-3 (Cell Signaling Cat. #9661) and SSEA1 (Biolegend Cat. #12560). c. Report whether the cell lines were tested for mycoplasma contamination.
Eukaryotic cell lines
No eukaryotic cell lines were used.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study.
For BD/PK and safety studies in mice, female BALB/c mice were used. For safety and toxicology studies in rats, male and female Crl:CD(SD) Sprague Dawley rats were used (ca. 9 weeks old upon initiation of the study). For safety and toxicology in dogs, male and female Beagle dogs were used (ca. 9 -12 months old upon initiation of the study). For efficacy in the STAM NASH mouse model, female C57BL/6 mice (14-day pregnant) were used, which afforded newborn male and female C57BL/6 for the study. For efficacy in the carbon tetrachloride (CCl4) mouse model, female BALB/c mice (7 -8 weeks old upon initiation of the study) were used.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
